Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Rating of “Moderate Buy” from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $5.20.

Several brokerages have recently issued reports on CNTX. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, October 16th. HC Wainwright reduced their target price on shares of Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Guggenheim began coverage on shares of Context Therapeutics in a research note on Thursday, September 18th. They issued a “buy” rating and a $5.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of Context Therapeutics in a research note on Thursday, October 2nd. They issued an “overweight” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, October 8th.

Context Therapeutics Trading Down 4.9%

Shares of NASDAQ CNTX opened at $1.17 on Wednesday. The firm has a market capitalization of $104.95 million, a PE ratio of -3.25 and a beta of 1.93. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $2.38. The firm’s 50-day moving average is $1.03 and its 200-day moving average is $0.84.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). As a group, equities research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

An institutional investor recently raised its position in Context Therapeutics stock. Clear Harbor Asset Management LLC lifted its position in Context Therapeutics Inc. (NASDAQ:CNTX) by 60.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,804 shares of the company’s stock after acquiring an additional 35,000 shares during the period. Clear Harbor Asset Management LLC owned approximately 0.10% of Context Therapeutics worth $90,000 at the end of the most recent quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.